This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
ctla-4
CTLA-4
CD152; inhibitory receptor on T cells competing with CD28 for B7-1/B7-2 co-stimulation — suppresses T cell priming in lymph nodes. Blocked by ipilimumab (anti-CTLA-4 IgG1); combined with anti-PD-1 (nivolumab) as standard of care in advanced melanoma and RCC.
Entry Metadata
| Field | Value |
|---|---|
| ID | ctla-4 |
| Name | CTLA-4 |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-1736. · PubMed 8596936
- Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723. · PubMed 20525992
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23-34. · PubMed 26027431